Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA7 | P43166 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | XDH | P47989 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl 3,5-Dimethylbenzoate SCHEMBL334346 | 0.95 | CNR2 (0.66) | ATMCA12CA1CA2CA7 | |
| SCHEMBL166126 | 0.91 | TPMT (0.64) | ATMCA12CA1CA2CA7 | |
| SCHEMBL3351858 | 0.91 | ATM (0.53) | ATMCA12CA1CA2CA7 | |
| SCHEMBL147169 | 0.89 | CA1 (0.71) | ATMCA12CA1CA2CA7 | |
| SCHEMBL18938219 | 0.89 | ATM (0.52) | ATMCA12CA1CA2CA7 | |
| SCHEMBL18883015 | 0.88 | CNR2 (0.50) | ATMCA12CA1CA2CA7 | |
| SCHEMBL2259905 | 0.87 | CA12 (0.76) | ATMCA12CA1CA2CA7 | |
| SCHEMBL31208002 | 0.87 | CA12 (0.76) | ATMCA12CA1CA2CA7 | |
| SCHEMBL14577653 | 0.86 | SLC7A5 (0.49) | ATMCA12CA1CA2CA7 | |
| SCHEMBL12322614 | 0.86 | KDM4E (0.51) | ATMCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116947671-A | Semi-rigid nitrogen-containing six-membered aromatic carboxylic acid ligand and preparation method thereof | 四川轻化工大学 | 2023-10-27 | — | — | CN | claimed |
| CN-107540538-B | Composition, reaction system and method for preparing 5-methyl isophthalic acid | 黄石市利福达医药化工有限公司 | 2020-07-28 | — | — | CN | claimed |
| US-6653295-B2 | Protease inhibitor; viricide | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | claimed |
| US-20030100768-A1 | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-05-29 | — | — | US | claimed |
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-04-03 | — | — | US | claimed |
| WO-2002048116-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-20 | — | — | WO | claimed |
| WO-2002048157-A2 | IMIDAZOLIDINONES AND THEIR RELATED DERIVATIVES AS HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-20 | — | — | WO | claimed |
| WO-2024199063-A1 | PHOSPHORUS OR SULFUR-CONTAINING MACROCYCLE AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20240115719-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | AJINOMOTO CO., INC. (JP) | 2024-04-11 | — | — | US | disclosed |
| US-11903895-B2 | Compression garment apparatus | KOYA MEDICAL, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| WO-2024024490-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER FILM | 日産化学株式会社 | 2024-02-01 | — | — | WO | disclosed |
| EP-4306535-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED USING SAME | AJINOMOTO CO., INC. (JP) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023238920-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER FILM TO REDUCE ENVIRONMENTAL IMPACT | 日産化学株式会社 | 2023-12-14 | — | — | WO | disclosed |
| WO-2002048116-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002048157-A2 | IMIDAZOLIDINONES AND THEIR RELATED DERIVATIVES AS HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002040701-A2 | ENERGY TRANSFER LABELS WITH MECHANICALLY LINKED FLUOROPHORES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-0774457-A1 | Substituted benzodicarboxylic acid diguanidines, process for their preparation, and their use as medicament or diagnostic agent | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-21 | — | — | EP | disclosed |
| EP-0538416-A4 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0538416-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. | RHONE POULENC RORER INT (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992004315-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115719-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | IGLV6-57, SSB, FCGR3B | ATM 3772/4885CA12 89/4885CA1 189/4885 |
| US-20030100768-A1 | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors | PRSS1, SPINT2, SERPINB1 | ATM 4010/4885CA12 4239/4885CA1 3646/4885 |
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | PRSS1, SERPINB1, SPINT2 | ATM 4408/4885CA12 4025/4885CA1 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.